Products
Ompekimig Biosimilar Trispecific Antibody (IL-13 × IL-4 × IL-33) for Research
Cat No.: GMP-Bios-INN-1314
Anti-IL13 therapeutic antibody (Pre-made Ompekimig biosimilar,Trispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ompekimig (development code PF-07264660) is a trispecific antibody targeting IL-4, IL-13, and IL-33. It is developed by Pfizer for inflammatory conditions. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1314-1mg | 1mg | |
| GMP-Bios-INN-1314-10mg | 10mg | |
| GMP-Bios-INN-1314-100mg | 100mg | |
| GMP-Bios-INN-1314-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ompekimig biosimilar, Trispecific Mixed mAb and scFv, Anti-IL13;IL4;IL33 Antibody: Anti-IL-13/P600/BCGF-1/BCGF1 therapeutic antibody |
| INN Name | Ompekimig |
| Target | IL13;IL4;IL33 |
| Format | Trispecific Mixed mAb and scFv; Bispecific entry |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
